Sarah Bird is at the Institute of Cancer Research, London SM2 5NG, UK and at the Royal Marsden Hospital NHS Foundation Trust, London. Charlotte Pawlyn is at the Institute of Cancer Research, London ...

Information on the disease and treatments, assistance with insurance, and transportation are among the types of support needed by patients with multiple myeloma to improve outcomes and overall burden.

Io Therapeutics, Inc., a privately held pharmaceutical company headquartered in Spring, Texas; announced today publication online in Scientific Reports -- Nature, of collaborative studies with Duke ...

With optimal treatment, myeloma isn't immediately life-threatening. Many patients live for years after their diagnosis, often ...

Survival in myeloma is clearly being prolonged,” says Mikhael. “Whereas historically, we saw a greater impact in younger ...

Immunotherapy is already improving treatment options for many cancer types, but research groups keep exploring ways to boost the body's immune response against the tumor. Multiple myeloma remains ...

While it’s not as well-known as, say, leukemia or melanoma, multiple myeloma is the second most common blood cancer in adults, according to the Cancer Research Institute. “Multiple myeloma is a cancer ...

The recent FDA approval of teclistamab (Tecvayli) and daratumumab and hyaluronidase-fihj (Darzelex Faspro) marks a major ...

Multiple myeloma, often referred to simply as myeloma, is a complex and frequently misunderstood blood cancer that originates in the bone marrow and affects the immune system. As the second most ...